Adalimumab (®Humira)  induction 80mg (3 +0) or 40mg (6 +0) then balance to week 14 40mg (2+2) then continuing to last dose week 22 (2+5)

Adalimumab Biosimilars (®Amgevita, ®Hadlima, ®Hyrimoz, ®Idacio) -Streamline only available ( FCD 11524/LCD 11631/UC 11579),   for these biosimilars (ITEM CODE: PEN 12353E/2D/34E, SYRINGE #12367X/437N/25Q )

Phone: 1800 700 270 option 6

Golimumab (Simponi): is an anti-tumour necrosis factor (TNF) alpha treatment delivered through under-the-skin injection monthly. The therapy is effective and offers patients a convenient option for a self-administered anti-TNF, especially helpful for those who have to travel a long distance to receive infusions. It is pbs listed for ulcerative colitis not Crohn's.

SIMPONI^® Dosing: 4-week dosing after 3 starter injections

.

Induction: 100mg  3+0 and 1+1,  with 12 week review. continuing 1+5anti-adhesion therapies

Vedolizumab (Entyvio):

Iintravenous: Powder for Injection is supplied as a sterile, white to off-white lyophilized cake or powder in a single-use vial. Each single-use vial contains 300 mg of vedolizumab. Each pack of ENTYVIO contains 1 glass vial

Subcutaneous: after minimum 2 IV doses - get the balance or switch at any time.  108mg/0.68mL PEN every 2 weekse

Initial: IV 2 doses wk 0, 2 then week -16 (6 pens) review 12 weeks = script IV 1+1 plus Pen 2+2 OR  if IV 3 dose (wk 0,2,6)  then  wk 14-16 PEN = script IV 1+2 then PEN 2+0

Switching IV to SCI during continuing - submit new CDAI/Mayo and get script 2+5 ie. 12 PENS for 26 weeks OR if not submitting new CDAI/MAYO you only get balance eg. after two IVI (week 0 and 8)  you switch, you get balance from week 16 -26 for 8 weeks only ie. PEN 2+2

Grandfathering - need initial form with past data proving eligibility PLUS continuing form showing remission PLUS cover letter.

anti IL12/23 therapy

Ustekinumab (Stelara):  is a human IgG1κ monoclonal antibody that binds to a subunit and inhibits the biological activity of the proinflammatory cytokines interleukin (IL)-12 and IL-23, which are involved in the pathophysiology of Crohn’s disease. It is administered as a one time intravenous, induction tiered dose (260–520 mg) based on body weight (ustekinumab 130 mg/26 mL injection, 26 mL vial)

• ≤55 kg: 260 mg IV
• >55 kg to 85 kg: 390 mg IV
• >85 kg: 520 mg IV

It takes at least 1 hour to receive the full dose of medicine. After the one-time IV infusion,  STELARA^® is given as an 90mg injection under the skin (as two subcutaneous 45mg injections  in 0.5 mL vials) every 8 weeks. There are 6 injections during the first year of treatment. The doctor can administer at his or her office, or  decide if the patient or a caregiver may give injections at home.

induction  wk0 IV 2-4 +0 then wk 8 SCI 2 +0 - review at 12 weeks, then continuation 2+2